Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia

Blood

Volumn 118, Issue 19, 2011, Pages 5201-5210

  Yan, Xiao Jie ^a   Dozmorov, Igor ^b   Li, Wentian ^a   Yancopoulos, Sophia ^a   Sison, Cristina ^a   Centola, Michael ^b   Jain, Preetesh ^a   Allen, Steven L ^a,c,d   Kolitz, Jonathan E ^a,c,d   Rai, Kanti R ^a,d,e   Chiorazzi, Nicholas ^a,c,d,f   Sherry, Barbara ^a,c,d  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD38 ANTIGEN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 81155133323     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-342436     Document Type: Article

References (50)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
2. Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol. 2010;20(6):377-383.
3. Ghia P, Circosta P, Scielzo C, et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol. 2005;294:135-145. (Pubitemid 41491253)
4. Scielzo C, Ten Hacken E, Bertilaccio MT, et al. How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection. Leuk Lymphoma. 2010;51(8):1371-1374.
5. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114(16):3367-3375.
6. Schröttner P, Leick M, Burger M. The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact. Ann Hematol. 2010;89(5):437-446.
7. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461-466. (Pubitemid 34232911)
8. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002;100(4):1215-1219. (Pubitemid 34864274)
9. Lai R, O'Brien S, Maushouri T, et al. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer. 2002;95(5):1071-1075. (Pubitemid 34925359)
10. Fayad L, Keating MJ, Reuben JM, et al. Interleukin- 6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001;97(1):256-263. (Pubitemid 32061268)
11. Anand M, Chodda SK, Parikh PM, Nadkarni JS. Dysregulated cytokine production by monocytes from chronic lymphocytic leukemia patients. Cancer Biother Radiopharm. 1998;13(1):43-48. (Pubitemid 28124461)
12. Kara IO, Sahin B, Gunesacar R. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. Adv Ther. 2007; 24(1):29-40. (Pubitemid 46700863)
13. Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood. 2011;117(5):1662-1669.
14. Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica. 2011;96(3):408-416.
15. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113(13):3050- 3058.
16. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114(5):1029-1037.
17. Ghia P, Chiorazzi N, Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264(6):549-562.
18. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102(8):1515-1525. (Pubitemid 28492218)
19. Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. (Pubitemid 29430399)
20. Szodoray P, Alex P, Brun JG, Centola M, Jonsson R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol. 2004;59(6):592-599. (Pubitemid 38789229)
21. Hitchon CA, Alex P, Erdile LB, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol. 2004;31(12):2336-2346. (Pubitemid 39603079)
22. Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2(3):18-22.
23. Culhane AC, Thioulouse J, Perriere G, Higgins DG. MADE4: an R package for multivariate analysis of gene expression data. Bioinformatics. 2005;21(11):2789-2790. (Pubitemid 40852331)
24. Dozmorov I, Saban MR, Gerard NP, et al. Neurokinin 1 receptors and neprilysin modulation of mouse bladder gene regulation. Physiol Genomics. 2003;12(3):239-250. (Pubitemid 37139703)
25. Jarvis JN, Dozmorov I, Jiang K, et al. Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 2004;6(1):R15-R32.
26. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol. 2002;32(5):1403-1413. (Pubitemid 34546268)
27. Mahadevan D, Choi J, Cooke L, et al. Gene expression and serum cytokine profiling of low stage CLL identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as regulators of cell proliferation, survival and migration. Hum Genomics Proteomics. 2009:453634, 2009.
28. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000;95(2):627-632. (Pubitemid 30041679)
29. Takatsu K, Kouro T, Nagai Y. Interleukin 5 in the link between the innate and acquired immune response. Adv Immunol. 2009;101:191-236.
30. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
31. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol. 2009;183(7):4169-4175.
32. Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene. 2010;29(42):5653-5662.
33. Jablonska E, Kiersnowska-Rogowska B, Rogowski F, Parfienczyk A, Puzewska W, Bukin M. TNF family molecules in the serum of patients with B-cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma. 2005;46(9):1307-1312. (Pubitemid 41269297)
34. Rodriguez-Vita J, Lawrence T. The resolution of inflammation and cancer. Cytokine Growth Factor Rev. 2010;21(1):61-65.
35. Zucchetto A, Benedetti D, Tripodo C, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009;69(9):4001-4009.
36. Schuhknecht S, Duensing S, Dallmann I, Grosse J, Reitz M, Atzpodien J. Interleukin-12 inhibits apoptosis in chronic lymphatic leukemia (CLL) B cells. Cancer Biother Radiopharm. 2002;17(5):495-499. (Pubitemid 35231608)
37. Till KJ, Lin K, Zuzel M, Cawley JC. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood. 2002;99(8):2977-2984. (Pubitemid 34525388)
38. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9(4):532-562. (Pubitemid 26366537)
39. Morel PA, Oriss TB. Crossregulation between Th1 and Th2 cells. Crit Rev Immunol. 1998;18(4):275-303. (Pubitemid 28364148)
40. Trentin L, Cerutti A, Zambello R, et al. Interleukin- 15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood. 1996;87(8):3327-3335.
41. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;8749-8762.
42. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J. 2010;16(4):392-398.
43. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595-601. (Pubitemid 44134092)
44. Jain P, Javdan M, Feger F, et al. Elevated IL-17 Producing cells (Th17 and non-Th17) in different CLL microenvironments: correlation with overall survival, prognostic relevance and phenotypic heterogeneity. Blood. 2011;116(21):2442.
45. Halvorsen EH, Stronen E, Hammer HB, Goll GL, Sollid LM, Molberg O. Interleukin-15 induces interleukin- 17 production by synovial T cell lines from patients with rheumatoid arthritis. Scand J Immunol. 2011;73(3):243-249.
46. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6(7):405-418.
47. Wierda WG, Chiorazzi N, Dearden C, et al. Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk. 2010;10(5):369-378.
48. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol. 2006;7(6):480-488. (Pubitemid 43796153)
49. Chanan-Khan A, Miller KC, Lawrence D, et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer. 2011;117(10):2127-2135.
50. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood. 2005;106(3):1012- 1020. (Pubitemid 41076448)